MeCo Diagnostics


MeCo Diagnostics is a venture-backed startup developing predictive biomarker tests to unlock low-cost, low-toxicity targeted therapy for cancer. Our Phase 2 study reveals our first-in-class test matches patients with early-stage luminal breast cancer to a highly effective repurposed therapy that is twice as effective as the best targeted therapy currently available.